Okamoto M - Search Results

1

Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity.

Takeuchi M, Okamoto M, Okamoto R, Kinoshita H, Yamaguchi Y, Watanabe N. Takeuchi M, et al. Among authors: okamoto m, okamoto r. Peptides. 2018 Apr;102:8-15. doi: 10.1016/j.peptides.2018.01.014. Epub 2018 Jan 31. Peptides. 2018. PMID: 29391187

2

Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs.

Takeuchi M, Okamoto M, Tamura M, Murase T, Watanabe N. Takeuchi M, et al. Among authors: okamoto m. Drug Res (Stuttg). 2019 Sep;69(9):479-486. doi: 10.1055/a-0885-1429. Epub 2019 May 13. Drug Res (Stuttg). 2019. PMID: 31083740

3

A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models.

Okamoto M, Fuchigami M, Suzuki T, Watanabe N. Okamoto M, et al. Biol Pharm Bull. 2012;35(11):2069-74. doi: 10.1248/bpb.b12-00528. Biol Pharm Bull. 2012. PMID: 23123476 Free article.

4

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model.

Okamoto M, Suzuki T, Watanabe N. Okamoto M, et al. J Pharmacol Pharmacother. 2013 Jul;4(3):208-10. doi: 10.4103/0976-500X.114605. J Pharmacol Pharmacother. 2013. PMID: 23960428 Free PMC article. No abstract available.

5

GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice.

Nakamura T, Tanimoto H, Okamoto M, Takeuchi M, Tsubamoto Y, Noda H. Nakamura T, et al. Among authors: okamoto m. Diabetes Metab Syndr Obes. 2021 Mar 9;14:1095-1105. doi: 10.2147/DMSO.S297353. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 33727843 Free PMC article.

6

Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice.

Nakamura T, Tanimoto H, Mizuno Y, Okamoto M, Takeuchi M, Tsubamoto Y, Noda H. Nakamura T, et al. Among authors: okamoto m. Obes Sci Pract. 2018 Mar 25;4(2):194-203. doi: 10.1002/osp4.164. eCollection 2018 Apr. Obes Sci Pract. 2018. PMID: 29670757 Free PMC article.

7

Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.

Ishiwata Y, Okamoto M, Yokochi S, Hashimoto H, Nakamura T, Miyachi A, Naito Y, Yoshikawa T. Ishiwata Y, et al. Among authors: okamoto m. J Pharm Pharmacol. 2003 Feb;55(2):229-37. doi: 10.1211/002235702478. J Pharm Pharmacol. 2003. PMID: 12635655

8

Susceptibility to recombinant SARS-CoV-2 spike protein entry in the lungs of high-fat diet-induced obese mice.

Gotoh K, Satoh F, Uesugi H, Noguchi T, Matsuda N, Sada K, Miyamoto S, Ozeki Y, Yoshida Y, Okamoto M, Masaki T, Kawabe T, Shibata H. Gotoh K, et al. Among authors: okamoto m. FASEB J. 2024 May 31;38(10):e23656. doi: 10.1096/fj.202301864RR. FASEB J. 2024. PMID: 38752523

9

Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment.

Masui H, Kawada K, Itatani Y, Hirai H, Nakanishi Y, Kiyasu Y, Hanada K, Okamoto M, Hirata W, Nishikawa Y, Sugimoto N, Tamura T, Sakai Y, Obama K. Masui H, et al. Among authors: okamoto m. Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02710-x. Online ahead of print. Br J Cancer. 2024. PMID: 38750114

10

Microhardness Measurements on Tooth and Alveolar Bone in Rodent Oral Disease Models.

Okamoto M, Yamashita S, Memida T, Mendonca M, Brueckner S, Nakamura S, Shindo S, Achong-Bowe R, Thompson J, Han X, Kawai T, Suzuki M. Okamoto M, et al. J Vis Exp. 2024 Apr 26;(206). doi: 10.3791/66583. J Vis Exp. 2024. PMID: 38738893

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,741 results

Search Page